Project Grant R01EB039066
Award Date 8/1/26
Completion Date 7/31/30
Dollars Obligated $3.8M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke (NINDS), part of the Department of Health and Human Services National Institutes of Health, awarded Case Western Reserve University $189,000 on July 20, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). Case Western Reserve University, through its Office of Research Administration in affiliation with University Hospitals of Cleveland, will conduct a randomized, sham-controlled, parallel-group feasibility trial...
- The National Center for Complementary and Integrative Health (NCCIH), a component of the Department of Health and Human Services National Institutes of Health, awarded $407,856 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on August 1, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). The recipient will conduct research examining how alpha-frequency transcranial alternating current stimulation (tACS) targeting...
- The National Institute of Neurological Disorders and Stroke (part of the Department of Health and Human Services National Institutes of Health) awarded Oregon Health & Science University $5.363 million on August 18, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to optimize spinal cord stimulation parameters for pain and itch management. The research investigates how epidural spinal cord stimulation engages dorsal horn circuits, specifically targeting neuropeptide Y...
- The National Institute of Neurological Disorders and Stroke awarded The Ohio State University $10.115 million on September 12, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a prospective observational study modeling diverse experiences and longitudinal trajectories of acute pain in emergency department settings. The study—titled MODEL-PAIN (MOdeling Diverse Experiences and Longitudinal trajectories of pain)—will enroll 2,400 emergency department patients and...
- The National Institute of Neurological Disorders and Stroke awarded The University of Chicago $677,636 on August 15, 2026, to develop programmable lithium-ion delivery devices for motor-sparing neuropathic pain therapy under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The project introduces a lithium-delivering bioelectronic platform with AI-enabled closed-loop control that provides programmable, localized, and reversible conduction...
- The National Institute of Neurological Disorders and Stroke awarded the University of Rochester $2,197,287 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a Phase III confirmatory clinical trial of daily, wireless, home-based transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN). The trial will evaluate TENS efficacy in relieving neuropathic pain in cancer patients who have developed CIPN—a common...
- The National Institute of Neurological Disorders and Stroke awarded the Regents of the University of Minnesota a cooperative agreement valued at $769,903 on August 1, 2026, to conduct a feasibility and pilot trial of a novel invasive brain stimulation approach for chronic neuropathic pain. The study combines precision functional mapping and individualized neurostimulation targeting the somato-cognitive action network and cingulo-opercular network—two key circuits in pain processing—to address...
- This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital $1.130557 million on August 20, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a non-viral lipid nanoparticle-delivered gene therapy for acute pain treatment as an alternative to opioids. The project focuses on creating a focal-delivery, non-opioid therapeutic targeting postsurgical pain as the primary indication, with secondary applications to acute exacerbations...
- The National Institute of Neurological Disorders and Stroke awarded the University of Massachusetts Lowell $2.272 million on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to discover novel, non-opioid, non-addictive analgesics derived from marine microbial natural products. The award funds a phenotypic screening effort combining human induced pluripotent stem cell sensory neurons and glia cultured on multi-well microelectrode arrays to characterize sensory neuron...